3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Hepatocellular
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
24
Neoplasms
14
Melanoma
9
Endometrial Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Cholangiocarcinoma
6
Stomach Neoplasms
4
Recurrence
4
Carcinoma
4
Biliary Tract Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Lymphoma
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Paraganglioma, Extra-Adrenal
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Lung Neoplasms
2
Liver Neoplasms
2
Glioma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, Hurthle cell
1
Interventions
Sunitinib
3
Thymectomy
2
Taxes
2
Prednisone
2
Pemetrexed
2
Paclitaxel
2
Octreotide
2
Imatinib Mesylate
2
Erlotinib Hydrochloride
2
Cisplatin
2
Carboplatin
2
vorolanib
1
regorafenib
1
pembrolizumab
1
olaparib
1
lenvatinib
1
entinostat
1
bosutinib
1
belinostat
1
atezolizumab
1
anetumab ravtansine
1
amrubicin
1
Ramucirumab
1
Radiotherapy
1
Radiosurgery
1
Radiofrequency Ablation
1
Psychiatric Rehabilitation
1
Prednisolone
1
Patient Comfort
1
Palliative Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Thymoma
×
lenvatinib
×
Clear all
NCT04710628
2026-02-19
PECATI
MedSIR
Phase 2
Completed
43 enrolled